Cargando…

Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms

OBJECTIVE: Immunoglobulin M antibodies against phosphorylcholine (anti‐PCs) may be protective in atherosclerosis, cardiovascular disease (CVD), and systemic lupus erythematosus (SLE). We study immunoglobulin G1 (IgG1) and immunoglobulin G2 (IgG2) anti‐PCs, with a focus on atherosclerosis and SLE. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiagarajan, D., Fiskesund, R., Frostegård, A., Steen, J., Rahman, M., Vikström, M., Lundström, S., Frostegård, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301871/
https://www.ncbi.nlm.nih.gov/pubmed/32392632
http://dx.doi.org/10.1002/acr2.11127
_version_ 1783547769357598720
author Thiagarajan, D.
Fiskesund, R.
Frostegård, A.
Steen, J.
Rahman, M.
Vikström, M.
Lundström, S.
Frostegård, J.
author_facet Thiagarajan, D.
Fiskesund, R.
Frostegård, A.
Steen, J.
Rahman, M.
Vikström, M.
Lundström, S.
Frostegård, J.
author_sort Thiagarajan, D.
collection PubMed
description OBJECTIVE: Immunoglobulin M antibodies against phosphorylcholine (anti‐PCs) may be protective in atherosclerosis, cardiovascular disease (CVD), and systemic lupus erythematosus (SLE). We study immunoglobulin G1 (IgG1) and immunoglobulin G2 (IgG2) anti‐PCs, with a focus on atherosclerosis and SLE. METHODS: We determined anti‐PCs by using the enzyme‐linked immunosorbent assay in 116 patients with SLE and 110 age‐ and sex‐matched controls. For functional studies, we used three in‐house–generated, fully human monoclonal IgG1 anti‐PCs (A01, D05, and E01). Apoptosis was induced in Jurkat T cells and preincubated with A01, D05, E01, or IgG1 isotype control, and effects on efferocytosis by human macrophages were studied. Anti‐PC peptide/protein characterization was determined using a proteomics de novo sequencing approach. RESULTS: IgG1, but not IgG2, anti‐PC levels were higher among patients with SLE (P = 0.02). IgG1 anti‐PCs were negatively associated with Systemic Lupus International Collaborating Clinics (SLICC) damage index and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores (odds ratio [OR]: 2.978 [confidence interval (CI): 0.876‐10.098] and OR: 5.108 [CI 1.3‐20.067], respectively) and negatively associated with CVD, atherosclerotic plaques, and echolucent plaques (potentially vulnerable plaques), but the association for the two former was not significant after controlling for confounders. D05 had a maximum effect on macrophage efferocytosis efficiency, followed by A01 and E01. The monoclonal antibodies showed differential binding specificity to PC and PC‐associated neoepitopes. A peptide analysis showed a difference in the complementarity‐determining region 3 of the three IgG1 anti‐PC clones that are crucial for recognition of PC on apoptotic cell surfaces and other neoepitopes. CONCLUSION: IgG1 anti‐PCs are negatively associated with disease activity and disease damage in SLE, but the negative association with CVD is also dependent on confounding risk factors. One potential underlying mechanism could be increased clearance of dead cells.
format Online
Article
Text
id pubmed-7301871
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73018712020-06-19 Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms Thiagarajan, D. Fiskesund, R. Frostegård, A. Steen, J. Rahman, M. Vikström, M. Lundström, S. Frostegård, J. ACR Open Rheumatol Original Articles OBJECTIVE: Immunoglobulin M antibodies against phosphorylcholine (anti‐PCs) may be protective in atherosclerosis, cardiovascular disease (CVD), and systemic lupus erythematosus (SLE). We study immunoglobulin G1 (IgG1) and immunoglobulin G2 (IgG2) anti‐PCs, with a focus on atherosclerosis and SLE. METHODS: We determined anti‐PCs by using the enzyme‐linked immunosorbent assay in 116 patients with SLE and 110 age‐ and sex‐matched controls. For functional studies, we used three in‐house–generated, fully human monoclonal IgG1 anti‐PCs (A01, D05, and E01). Apoptosis was induced in Jurkat T cells and preincubated with A01, D05, E01, or IgG1 isotype control, and effects on efferocytosis by human macrophages were studied. Anti‐PC peptide/protein characterization was determined using a proteomics de novo sequencing approach. RESULTS: IgG1, but not IgG2, anti‐PC levels were higher among patients with SLE (P = 0.02). IgG1 anti‐PCs were negatively associated with Systemic Lupus International Collaborating Clinics (SLICC) damage index and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores (odds ratio [OR]: 2.978 [confidence interval (CI): 0.876‐10.098] and OR: 5.108 [CI 1.3‐20.067], respectively) and negatively associated with CVD, atherosclerotic plaques, and echolucent plaques (potentially vulnerable plaques), but the association for the two former was not significant after controlling for confounders. D05 had a maximum effect on macrophage efferocytosis efficiency, followed by A01 and E01. The monoclonal antibodies showed differential binding specificity to PC and PC‐associated neoepitopes. A peptide analysis showed a difference in the complementarity‐determining region 3 of the three IgG1 anti‐PC clones that are crucial for recognition of PC on apoptotic cell surfaces and other neoepitopes. CONCLUSION: IgG1 anti‐PCs are negatively associated with disease activity and disease damage in SLE, but the negative association with CVD is also dependent on confounding risk factors. One potential underlying mechanism could be increased clearance of dead cells. John Wiley and Sons Inc. 2020-05-11 /pmc/articles/PMC7301871/ /pubmed/32392632 http://dx.doi.org/10.1002/acr2.11127 Text en © 2020 The Authors. ACR Open Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Thiagarajan, D.
Fiskesund, R.
Frostegård, A.
Steen, J.
Rahman, M.
Vikström, M.
Lundström, S.
Frostegård, J.
Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms
title Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms
title_full Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms
title_fullStr Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms
title_full_unstemmed Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms
title_short Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms
title_sort immunoglobulin g1 antibodies against phosphorylcholine are associated with protection in systemic lupus erythematosus and atherosclerosis: potential underlying mechanisms
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301871/
https://www.ncbi.nlm.nih.gov/pubmed/32392632
http://dx.doi.org/10.1002/acr2.11127
work_keys_str_mv AT thiagarajand immunoglobuling1antibodiesagainstphosphorylcholineareassociatedwithprotectioninsystemiclupuserythematosusandatherosclerosispotentialunderlyingmechanisms
AT fiskesundr immunoglobuling1antibodiesagainstphosphorylcholineareassociatedwithprotectioninsystemiclupuserythematosusandatherosclerosispotentialunderlyingmechanisms
AT frostegarda immunoglobuling1antibodiesagainstphosphorylcholineareassociatedwithprotectioninsystemiclupuserythematosusandatherosclerosispotentialunderlyingmechanisms
AT steenj immunoglobuling1antibodiesagainstphosphorylcholineareassociatedwithprotectioninsystemiclupuserythematosusandatherosclerosispotentialunderlyingmechanisms
AT rahmanm immunoglobuling1antibodiesagainstphosphorylcholineareassociatedwithprotectioninsystemiclupuserythematosusandatherosclerosispotentialunderlyingmechanisms
AT vikstromm immunoglobuling1antibodiesagainstphosphorylcholineareassociatedwithprotectioninsystemiclupuserythematosusandatherosclerosispotentialunderlyingmechanisms
AT lundstroms immunoglobuling1antibodiesagainstphosphorylcholineareassociatedwithprotectioninsystemiclupuserythematosusandatherosclerosispotentialunderlyingmechanisms
AT frostegardj immunoglobuling1antibodiesagainstphosphorylcholineareassociatedwithprotectioninsystemiclupuserythematosusandatherosclerosispotentialunderlyingmechanisms